Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 216-222

  Gu, Wei ^a   Liu, Long ^a   Fang, Fan Fu ^a   Huang, Feng ^a   Cheng, Bin Bin ^a   Li, Bai ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; ATP binding cassette transporters; Bufalin; Hepatocellular carcinoma; Multidrug resistance

Indexed keywords

BUFALIN; FLUOROURACIL; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BAX; PROTEIN BCL XL; THYMIDYLATE SYNTHASE; VERAPAMIL;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA EXTRA LARGE GENE; BCL 2 ASSOCIATED X PROTEIN GENE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE PROTEIN 1 GENE; P GLYCOPROTEIN GENE; PRIORITY JOURNAL; THYMIDYLATE SYNTHASE GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BUFANOLIDES; CALCIUM CHANNEL BLOCKERS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LIVER NEOPLASMS; MEDICINE, CHINESE TRADITIONAL; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; THYMIDYLATE SYNTHASE; VERAPAMIL;

EID: 84891913359     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2817     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer. Lyon, France, 2010 [http://globocan.iarc.fr].
2. Marin JJ, Romero MR and Briz O: Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem 17: 709-740, 2010.
3. Zhu AX: Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11: 790-800, 2006.
4. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G and Johnson P: Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 15: 1008-1014, 2008.
5. Kim JH, Chung JB, Park IS, et al: Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. Yonsei Med J 34: 35-44, 1993.
6. Ferry DR, Traunecker H and Kerr DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070-1081, 1996.
7. Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165, 2003.
8. Meng Z, Yang P, Shen Y, et al: Pilot study of huachansu in patients with hepatocellular carcinoma, non-small-cell lung cancer, or pancreatic cancer. Cancer 115: 5309-5318, 2009.
9. Zhang LS, Nakaya K, Yoshida T and Kuroiwa Y: Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 178: 686-693, 1991.
10. Watabe M, Ito K, Masuda Y, Nakajo S and Nakaya K: Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 16: 779-787, 1998.
11. Yeh JY, Huang WJ, Kan SF and Wang PS: Effects of bufalin and cinobufagin on the proliferation of androgen-dependent and -independent prostate cancer cells. Prostate 54: 112-124, 2003.
12. Li D, Qu X, Hou K, et al: PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs 20: 59-64, 2009.
13. Han KQ, Huang G, Gu W, Su YH, Huang XQ and Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol 13: 3374-3379, 2007.
14. Gu W, Fang FF, Li B, Cheng BB and Ling CQ: Characterization and resistance mechanisms of a 5-fluorouracil-resistant hepatocellular carcinoma cell line. Asian Pac J Cancer Prev 13: 4807-4814, 2012.
15. Shi LX, Ma R, Lu R, et al: Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. Cancer Lett 269: 101-110, 2008.
16. Robert J and Jarry C: Multidrug resistance reversal agents. J Med Chem 46: 4805-4817, 2003.
17. Ramachandran C, Rabi T, Fonseca HB, Melnick SJ and Escalon EA: Novel plant triterpenoid drug amooranin overcomes multidrug resistance in human leukemia and colon carcinoma cell lines. Int J Cancer 105: 784-789, 2003.
18. Ravizza R, Gariboldi MB, Molteni R and Monti E: Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells. Oncol Rep 20: 625-630, 2008.
19. Xu M, Sheng LH, Zhu XH, Zeng SB and Zhang GJ: Reversal effect of Stephania tetrandra-containing Chinese herb formula SENL on multidrug resistance in lung cancer cell line SW1573/2R120. Am J Chin Med 38: 401-413, 2010.
20. Han Y, Bu LM, Ji X, Liu CY and Wang ZH: Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line. Chin J Dig Dis 6: 82-86, 2005.
21. Borska S, Sopel M, Chmielewska M, Zabel M and Dziegiel P: Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 15: 857-870, 2010.
22. Tang PM, Chan JY, Zhang DM, et al: Pheophorbide a, an active component in Scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2. Cancer Biol Ther 6: 504-509, 2007.
23. Sun BT, Zheng LH, Bao YL, Yu CL, Wu Y, Meng XY and Li YX: Reversal effect of Dioscin on multidrug resistance in human hepatoma HepG2/adriamycin cells. Eur J Pharmacol 654: 129-134, 2011.
24. Huang M, Jin J, Sun H and Liu GT: Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 62: 1015-1026, 2008.
25. Fong WF, Wan CK, Zhu GY, Chattopadhyay A, Dey S, Zhao Z and Shen XL: Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med 73: 212-220, 2007.
26. Yu CH, Kan SF, Pu HF, Jea Chien E and Wang PS: Apoptotic signaling in bufalin-and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci 99: 2467-2476, 2008.
27. Hong SH and Choi YH: Bufalin induces apoptosis through activation of both the intrinsic and extrinsic pathways in human bladder cancer cells. Oncol Rep 27: 114-120, 2012.
28. Yin JQ, Shen JN, Su WW, et al: Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines. Acta Pharmacol Sin 28: 712-720, 2007.
29. Takai N, Ueda T, Ishii T, et al: Effects of bufalin on the proliferation of human choriocarcinoma cells. Int J Gynecol Cancer 21: 1105-1109, 2011.
30. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med 21: 637-643, 2008.
31. Xie CM, Chan WY, Yu S, Zhao J and Cheng CH: Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med 51: 1365-1375, 2011.
32. Nasu K, Nishida M, Ueda T, Takai N, Bing S, Narahara H and Miyakawa I: Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Hum Reprod 11: 817-823, 2005.
33. Jing Y, Watabe M, Hashimoto S, Nakajo S and Nakaya K: Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res 14: 1193-1198, 1994.
34. Watabe M, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem 271: 14067-14072, 1996.
35. Qi F, Inagaki Y, Gao B, et al: Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci 102: 951-958, 2011.
36. Zhang N, Yin Y, Xu SJ and Chen WS: 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13: 1551-1569, 2008.